Drug Topics

APRIL 8, 2024

Researchers addressed pharmacists’ role in mitigating drug shortages.

201

201

STAT

APRIL 8, 2024

Anyone can now walk into a pharmacy in the United States and buy oral contraceptives over the counter without a prescription, thanks to the FDA’s approval of norgestrel (Opill). This change reflects the drug’s safety and the public health imperative to ensure wider access to birth control. But another safe class of medicine that addresses a massive public health need remains unavailable except by prescription: the antidepressants known as selective serotonin reuptake inhibitor

FDA 145

FDA 145

Drug Topics

APRIL 8, 2024

Due to the increased possibility of adverse pregnancy outcomes associated with methotrexate and leflunomid, it is crucial that patients with rheumatoid arthritis (RA) engage in thorough consultations with their physicians regarding pregnancy planning.

144

144

STAT

APRIL 8, 2024

For the vast majority of pancreatic cancer cases, the tumor grows undetected until it has already spread locally or to distant parts of the body. That means most patients, over 80% by some estimates, are diagnosed when it’s already too late to do surgery — depriving them of their best chance for a cure. “For the majority of patients, we cannot resect the tumor.

145

145

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Fierce Healthcare

APRIL 8, 2024

Grow Therapy, a mental health technology startup, picked up $88 million in fresh funding to grow its footprint and launch more partnerships with payers. | Grow Therapy, a mental health technology startup, picked up $88 million in fresh funding to grow its footprint and launch more partnerships with payers.

135

135

STAT

APRIL 8, 2024

The country’s biggest hospital chain, HCA Healthcare , told the Centers for Medicare and Medicaid Services it doled out almost $1 billion more in financial assistance to needy patients than it reported on its financial statement in 2022, helping the enormously profitable company extract billions of dollars from taxpayer-funded programs. It’s normal for hospital systems to report more charity care — free and discounted care provided to low-income patients — in their an

Hospitals 144

Hospitals 144

STAT

APRIL 8, 2024

The world’s first recipient of a kidney transplant from a genetically modified pig experienced a rejection episode before recovering and leaving the hospital last week, a Massachusetts General Hospital doctor told STAT. But in his first few days back at home in Weymouth, Mass., the patient — 62-year-old Richard Slayman — had shown no further signs of organ distress.

Hospitals 144

Hospitals 144

Fierce Pharma

APRIL 8, 2024

Merely hours after Bristol Myers Squibb’s Abecma secured the FDA’s blessing to break into earlier treatment of multiple myeloma, Johnson & Johnson and Legend Biotech’s Carvykti received a simil | Merely hours after Bristol Myers Squibb’s Abecma secured the FDA’s blessing to break into earlier treatment of multiple myeloma, Johnson & Johnson and Legend Biotech’s Carvykti received a similar go-ahead—but in an even earlier setting and with expanded manufacturing specifications.

128

128

STAT

APRIL 8, 2024

It’s been a year since states began the process of Medicaid redetermination, going through their Medicaid rolls that had been frozen through the Covid-19 emergency period. According to data from KFF , about 21% of the people who were enrolled prior to the redetermination, or close to 20 million, lost coverage, while 45%, or 42 million, were confirmed.

136

136

Fierce Pharma

APRIL 8, 2024

With Enhertu at the heart of AstraZeneca and Daiichi Sankyo’s respective goals for oncology growth, the partners have significantly expanded the antibody-drug conjugate’s (ADC's) reach in the U.S.< | With Enhertu at the heart of AstraZeneca and Daiichi Sankyo’s respective goals for oncology growth, the partners have significantly expanded the antibody-drug conjugate’s reach in the United States.

FDA 126

FDA 126

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

APRIL 8, 2024

A fully independent clinical trial researchers thought might disprove a cardiac device made by Shockwave Medical, the company that Johnson & Johnson is buying for $13 billion, ended up providing some support for the device’s utility. The data, presented Monday at the annual meeting of the American College of Cardiology and published in The Lancet , could bolster the case for the device, which is available in Europe and the U.K. but was previously rejected by the U.S.

FDA 126

FDA 126

PharmaVoice

APRIL 8, 2024

The market is huge, but will companies overcome the triple hurdles of payer hesitance, prescriber reluctance and sluggish consumer demand?

122

122

Fierce Pharma

APRIL 8, 2024

One hallmark of the FDA's accelerated approval pathway is the requirement that medicines prove their benefits in confirmatory trials. | Many cancer meds approved under the FDA's accelerated approval pathway from 2013 to 2017 didn't improve overall survival after more than five years of follow-up research, the study found.

FDA 119

FDA 119

STAT

APRIL 8, 2024

You’re reading the web version of Health Care Inc.,  STAT’s weekly newsletter  following the flow of money in medicine.  Sign up  to get it in your inbox every Monday.  The funny business of reporting charity care The concept of charity care is simple: It’s the free and discounted care that hospitals provide to low-income people.

Hospitals 119

Hospitals Insurance 119

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Fierce Pharma

APRIL 8, 2024

The third time is decidedly not the charm for Supernus and its Parkinson’s disease infusion pump. | The FDA refused to accept Supernus' first approval bid after the company acquired the med in 2020. The following year, the agency doled out a complete response letter, dashing Supernus' second try.

FDA 119

FDA 119

pharmaphorum

APRIL 8, 2024

Empower women's health with digital tools and technology. Learn about the latest advancements and resources to promote wellness and empowerment in women's health.

118

118

Pharmacy Times

APRIL 8, 2024

The treatment is indicated for adolescents at least 12 years of age who weigh at least 25 kg without a previous treatment history of antiretroviral therapies.

FDA 117

FDA 117

pharmaphorum

APRIL 8, 2024

SGLT2 inhibitors have transformed the treatment of heart failure in the last few years, but an attempt to extend their use into the setting of post-heart attack patients has suffered a setback.

118

118

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Healthcare

APRIL 8, 2024

Health insurers are gearing up to release their first-quarter results over the next several weeks, and a new analysis from Fitch Ratings finds that ongoing concern about utilization in Medicare Adv | A new analysis from Fitch Ratings finds that ongoing concern about utilization in Medicare Advantage has made for a cloudy outlook.

Insurance 115

Insurance 115

pharmaphorum

APRIL 8, 2024

Stay up to date with the latest pharma and biotech hires from March 2024, including notable companies like Sitryx, Oxford, and MaaT Pharma.

115

115

STAT

APRIL 8, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hi, it’s Meghana. Lots happened this past weekend! We have news for you from the annual meeting of the American Association for Cancer Research, and also from the annual meeting of the American College of Cardiology.

114

114

pharmaphorum

APRIL 8, 2024

Creating a winning playbook for consistent digital product success involves strategic planning, execution, and continuous improvement. Discover key strategies and practices to ensure your digital products achieve lasting success.

111

111

Pharmacy Times

APRIL 8, 2024

Current evidence and data regarding clozapine-resistant schizophrenia is unclear, but new treatment options are on the horizon that could show promise.

111

111

pharmaphorum

APRIL 8, 2024

Drugs from Ionis and Arrowhead Pharma that block apolipoprotein C-III (apoC-III) have shown their value in treating diseases associated with elevated triglyceride levels in two studies presented at the American College of Cardiology annual congress. The two companies are racing to bring their apoC-III inhibitors to market for severe hypertriglyceridaemia (HTG) and ultra-rare disorder familial chylomicronaemia syndrome (FCS).

111

111

Pharmacy Times

APRIL 8, 2024

New approaches for treating all schizophrenia symptoms by modulating dopamine and glutamate in non-traditional ways.

111

111

pharmaphorum

APRIL 8, 2024

FDA approves AstraZeneca and Daiichi Sankyo’s Enhertu for all HER2-positive solid tumours, in a first for both the HER2 inhibitor and ADC category.

FDA 111

FDA 111

Pharmacy Times

APRIL 8, 2024

The finding did not reach statistical significance in the primary composite endpoint.

Hospitals 109

Hospitals 109

pharmaphorum

APRIL 8, 2024

Less than half of the cancer therapies given accelerated approval by the FDA in 2013 to 2017 showed a clinical benefit in a confirmatory trial within the next five years

FDA 110

FDA 110

STAT

APRIL 8, 2024

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because the usual routine of online meetings, phone calls, and deadlines has inevitably returned. But you knew this would happen, yes? After all, what can you do? The world, such as it is, continues to spin. So in hopes of nudging it in a better direction, we are brewing cups of stimulation.

FDA 109

FDA 109

Pharmacy Times

APRIL 8, 2024

Investigators reported a low incidence of adverse events after simultaneous vaccination against seasonal influenza and respiratory syncytial virus.

Vaccines 107

Vaccines 107

STAT

APRIL 8, 2024

File this under “Not a moment too soon.” After years of back-and-forth deliberations, the U.S. Food and Drug Administration has agreed to review a rare disease drug developed by a small company that planned to shelve further work if the agency did not take this long-sought step. Specifically, the FDA accepted a new drug application from Stealth BioTherapeutics for a treatment to combat Barth syndrome, which causes an enlarged heart, muscle weakness, and a shortened life expectancy.

FDA 108

FDA 108

PharmaVoice

APRIL 8, 2024

GenAI is profoundly reshaping various facets of the pharmaceutical industry. Projections indicate that the global GenAI market in pharma will soar to USD 2258.1 million by 2032.

105

105

Pharmaceutical Commerce

APRIL 8, 2024

In an interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, Value & Access Advisor, Schoonveld Advisory, offers his thoughts on lower drug prices in the US and provides a sneak peak into future PC features.

105

105